1 William Sansum Diabetes Center , Santa Barbara, CA.
2 T1D Exchange , Boston, MA.
Diabetes Technol Ther. 2017 Dec;19(12):744-748. doi: 10.1089/dia.2017.0259. Epub 2017 Oct 27.
We sought to determine the real-life experiences of individuals traveling long distance (across five or more time-zones) with type 1 diabetes (T1D). Five hundred three members of the T1D Exchange online community ( www.myglu.org ) completed a 45-question survey about their travel experiences flying long distance. The cohort was stratified by duration of T1D and whether or not participants used continuous subcutaneous insulin infusion (CSII) therapy and/or a continuous glucose monitor (CGM). In the last 5 years, 71% of participants had flown long distance. When asked about their perceived "fear of flying," CSII users (with and without a CGM) reported their primary anxiety was "losing supplies," while non-CSII users described concerns over "unstable blood glucose (highs and lows)" (P < 0.05). In addition, 74% of participants reported more hypoglycemia and/or hyperglycemia while traveling overseas and 9% had avoided international travel altogether because of problems related to diabetes management. Furthermore, 22% of participants had run out of insulin at some point during a trip and 37% reported inadequate attention in current sources of information to the unpredictability of self-management needs while traveling. Especially problematic for individuals traveling with T1D are a lack of resources adequately addressing (1) protocols for emergencies while abroad, (2) how to navigate airport security, and (3) managing basal insulin rates when crossing time zones. A strong need exists for easily accessible, free resources for traveling with T1D that is tailored to both device use and duration of the disease.
我们旨在了解患有 1 型糖尿病(T1D)的个体长途旅行(跨越五个或更多时区)的实际体验。T1D 交换在线社区(www.myglu.org)的 503 名成员完成了一项关于其长途飞行旅行经历的 45 个问题的调查。该队列按 T1D 的持续时间以及参与者是否使用持续皮下胰岛素输注(CSII)疗法和/或连续血糖监测仪(CGM)进行分层。在过去的 5 年中,有 71%的参与者曾长途飞行。当被问及他们对“飞行恐惧”的看法时,使用 CSII(有和没有 CGM)的患者报告其主要焦虑是“供应品丢失”,而未使用 CSII 的患者则表示担心“血糖不稳定(高和低)”(P<0.05)。此外,有 74%的参与者报告在海外旅行时发生更多的低血糖症和/或高血糖症,有 9%的人因与糖尿病管理相关的问题而完全避免国际旅行。此外,有 22%的参与者在旅行过程中的某个时间点胰岛素用完,有 37%的参与者报告说,目前的信息来源对旅行中自我管理需求的不可预测性没有足够的关注。对于患有 T1D 的旅行者来说,尤其成问题的是缺乏资源来充分解决(1)在国外发生紧急情况的协议,(2)如何通过机场安检,以及(3)当穿越时区时管理基础胰岛素剂量的问题。迫切需要针对 T1D 旅行者的易于访问且免费的资源,这些资源应根据设备使用和疾病持续时间进行定制。